Skip to main content

Medicine at the Crick | The new medicine of DNA repair pathways: damage repair vulnerabilities in cancer



This virtual event is part of the Francis Crick Institute's 'Medicine at the Crick' series, which showcases major advances in biomedical science and raises awareness of the medical implications of major scientific advances. Each event comprises a series of talks and a panel discussion. 

The sixth event in this series, 'The new medicine of DNA repair pathways: damage repair vulnerabilities in cancer', will take place virtually on 11 February 2021 from 14:00 - 17:20 GMT.

Loss of DNA repair pathways is an early and frequent event in tumorigenesis. DNA repair-deficient cancers often become critically dependent on backup DNA repair pathways, which present an 'Achilles heel' that can be targeted to eliminate cancer cells.

This is the basis of synthetic lethality and is exemplified by the success of poly(ADP-ribose) polymerase (PARP) inhibitors in treating BRCA-deficient breast and ovarian cancers. However, new therapeutic strategies are urgently needed to overcome acquired and innate PARP inhibitor resistance and to exploit other DNA repair deficiencies. This meeting will discuss the discovery, development, success and clinical challenges of PARP inhibitors and the current efforts to develop new DNA repair inhibitors to exploit other vulnerabilities in cancer.

Speakers include ​​​Dr Graeme Smith (Artios Pharma), Prof Charlie Gourley (The University of Edinburgh), Prof Ruth Plummer (Newcastle University), Dr Michael Zinda (Repare Therapeutics) and Ms Kate Bingham (SV Health Investors).

This event is free. Book your place here